Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
Abstract The previous studies had demonstrated the promising effectiveness and acceptable safety of pyrotinib in patients with HER2‐positive metastatic breast cancer. We aimed to investigate the real‐world data of pyrotinib in complex clinical practice and complement the findings of clinical trials....
Guardado en:
Autores principales: | Chao Li, Xiaoli Bian, Zhaoyun Liu, Xinzhao Wang, Xiang Song, Wei Zhao, Yansong Liu, Zhiyong Yu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/357c177e18c045569d6a81b2ad610d5a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021) -
The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Ilana Schlam, et al.
Publicado: (2021) -
Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017) -
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
por: Serafin Morales, et al.
Publicado: (2021) -
HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
por: Saglican,Yesim, et al.
Publicado: (2015)